Wave Life Sciences Shares Plunge 49.6% After Phase I Fat Loss Miss
Wave Life Sciences’ Phase I obesity trial of WVE-007 showed a 16.5% reduction in visceral fat-to-muscle ratio and a 1% drop in body weight at 240mg, while the 400mg cohort saw 5% visceral fat loss and 0.7% total fat reduction. Shares tumbled 49.6% after results fell below expectations.
1. Phase I Efficacy Results
In the INLIGHT study, participants receiving 240mg of WVE-007 achieved a 16.5% drop in visceral fat-to-muscle ratio, a 5% total fat reduction, a 3% waist circumference loss and a 2% lean mass increase after six months. The 400mg cohort saw a 5% visceral fat loss, 0.7% total fat reduction and a 0.2% lean mass decrease over three months due to a leaner baseline composition.
2. Safety and Tolerability
WVE-007 was safe and tolerable at doses up to 600mg, with no severe or serious treatment-emergent adverse events and no discontinuations. Sustained reductions in Activin E persisted for at least seven months, supporting potential once- or twice-yearly dosing schedules.
3. Market Reaction
Shares closed at $12.30 on March 25 and dropped 49.59% to $6.20 on March 26 following the underwhelming efficacy data. Investor sentiment was muted as the outcomes fell short of expectations for meaningful weight loss.
4. Next Steps
Wave plans to initiate Phase IIa dosing in the second quarter of 2026, testing WVE-007 as a monotherapy in patients with BMI between 35 and 50 kg/m2 and comorbidities. This trial will aim to demonstrate more pronounced weight-loss effects in a higher-risk population.